


# Borstkanker

DAG	TITEL	TIJD	LOCATIE
VRIJDAG 27.09.19	Multidisciplinary management of germline and somatic gene alterations in patients with metastatic breast cancer	14.15 -15.15	Pamplona Auditorium (Hal 2)
	Biosimilars use in oncology: clarifying concepts	16.00 -17.30	Valencia Auditorium (Hal 5)
	Is there a role for the addition of platinum-based chemotherapy to standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC)?	16.15 -17.15	Granada Auditorium (Hal 3)
	Partial breast radiation therapy: Which patients, when, and with what technique?	16.15 -17.25	Alicante Auditorium (Hal 3)
<i>Pfizer sponsored symposium:</i>	Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>Roche sponsored symposium:</i>	Multi-disciplinary perspectives on optimising patient outcomes in HER2-positive eBC	18:00 - 19:30	Cordoba Auditorium (Hal 7)
ZATERDAG 28.09.19	Tackling the treatment options in triple negative metastatic breast cancer	08.45 - 09.45	Salamanca Auditorium (Hal 3)
	Proffered Paper - Breast cancer, metastatic	10.15 -11.45	Barcelona Auditorium (Hal 2)
<i>Pfizer sponsored symposium:</i>	From clinical trials to practice: Changing the trajectory for patients with breast cancer	13.00 -14.30	Pamplona Auditorium (Hal 2)
<i>Lily sponsored symposium:</i>	The ABC's of CDK4/6 inhibitors. Who, When and Why in HR-positive/ HER2-Negative mBC	13.00 -14.30	Alicante Auditorium (Hal 3)
	Poster Discussion - Breast cancer, early stage	14.45 -16.00	Valencia Auditorium (Hal 5)
	Challenges in the management of luminal ER + mBC	16.30 -18.00	Madrid Auditorium (Hal 2)
ZONDAG 29.09.19	Poster Discussion - Breast cancer, metastatic	08.30 -09.50	Cordoba Auditorium (Hal 7)
	Practicing oncology in elderly cancer patients	10:15 -11:45	Alicante Auditorium (Hal 3)

<b>Novartis sponsored symposium:</b>	Tackling the diversity of triple negative early breast cancer (TNBC)	10.15 -11.45	Barcelona Auditorium (Hal 2)
	Optimising Patient Outcomes and Quality of Life in HR+, HER2- ABC	13:00 -14:30	Alicante Auditorium (Hal 3)
	Where will future technologies take us in metastatic breast cancer?	14.45 -16.15	Barcelona Auditorium (Hal 2)
<b>MAANDAG 30.09.19</b>	Treating young patients with BRCA-mutated early breast cancers	08.45 -09.45	Pamplona Auditorium (Hal 2)
<b>Samsung Bioepis sponsored symposium</b>	Quality Assurance to Optimize HER2+ Breast Cancer Treatment	13:00 -14:30	Toledo Auditorium (Hal 5)
	Proffered Paper - Breast cancer, early stage	14.45 -16.15	Bilbao Auditorium (Hal 5)
	Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients	16.30 -18.00	Madrid Auditorium (Hal 2)
<b>DINSDAG 01.10.19</b>	Congress Highlights 1 - The best of ESMO 2019	11.40 -12.20	Madrid Auditorium (Hal 2)



From Clinical Trials to Practice:

# CHANGING THE TRAJECTORY FOR PATIENTS WITH BREAST CANCER

## **INTRODUCTION:** Blazing the Trail in the Treatment of Breast Cancer

*Miguel Martin, MD, PhD*

## **CHARTING THE COURSE:** Novel Treatment Options for Patients with Germline BRCA-mutated Locally Advanced/Metastatic Breast Cancer

*Hope Rugo, MD*

## **ADVANCING THE PATH:** Selecting Treatment for Patients with Germline BRCA-mutated Locally Advanced/Metastatic Breast Cancer

*Johannes Ettl, MD*

## **PAVING THE WAY IN THE CLINIC:** Real-world Outcomes With CDK 4/6 Inhibitor Treatments for Locally Advanced/Metastatic Breast Cancer

*Adam Brufsky, MD, PhD*

## **PANEL Q&A**



**MIGUEL MARTIN**

Hospital General Universitario  
Gregorio Marañón  
Madrid, Spain



**HOPE RUGO**

University of San Francisco Helen Diller  
Family Comprehensive Cancer Center  
San Francisco, CA, USA



**JOHANNES Ettl**

Technische Universität München  
Munich, Germany



**ADAM BRUFsky**

UPMC Hillman Cancer Center  
Pittsburgh, PA, USA